Cai 2012.

Methods	This was a randomised, controlled, parallel clinical trial
Participants	1. Setting: The trial recruited participants from an outpatient dermatology department of a Chinese medicine hospital in Zhangzhou, China 2. Age: from 1.5 to 13 years of age 3. Sex (men/women): 49/35 4. Number of participants randomised: 84 5. T/C: 43/41
Interventions	I. Treatment group 1. Shenling Baizhu decoction with individualised modifications 1.1 Ingredients and dosage Dangshen (Radix salviae miltiorrhizae) 10 g Baizhu (Rhizoma atractylodis macrocephalae) 10 g Fuling (Poria) 15 g Baixianpi (Cortex dictamni) 10 g Yiyiren (Semen coicis) 15 g Shanyao (Rhizoma dioscoreae) 12 g Jiegen (Radix platycodi) 10 g Tufuling (Rhizoma smilacis glabrae) 12 g Mohanlian (Herba ecliptae) 15 g Nuzhenzi (Fructus ligustri lucidi) 10 g Gancao(Radix glycyrrhizae) 6 g 1.2 Administration Oral ingestion of the decoction 2 times daily 1.3 Duration of treatment 4 weeks 1.4 Follow up Did not state II. Control group 2. Loratadine tablet 2.1 Ingredients and dosage Loratadine 10 mg/tablet 2.2 Administration Oral ingestion 10 mg once daily 2.3 Duration of treatment 4 weeks 2.4 Follow up Did not state ‐ Topical application of triamcinolone acetonide acetate cream and vitamin B₆ cream were provided for both groups
Outcomes	1. Effectiveness rate 2. Adverse events Assessed at the end of the 4‐week treatment period
Notes	1. The trial investigator claimed that they included only those who were diagnosed with AD and identified as "spleen deficiency with dryness of blood" in Chinese medicine 2. We contacted the corresponding trial investigator for further information (such as the randomisation method, whether the study was a prospective design, etc). We received no reply